Baker Bros. Advisors’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Baker Bros. Advisors’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-979,016	Closed	-$7.87M	–	122
2018 Q2	$7.87M	Sell	979,016 -1,327,168	-58%	-$10.1M	0.06%	60
2018 Q1	$17.2M	Sell	2,306,184 -844,624	-27%	-$5.62M	0.15%	45
2017 Q4	$18.7M	Hold	3,150,808	–	–	0.16%	46
2017 Q3	$23.2M	Hold	3,150,808	–	–	0.19%	35
2017 Q2	$21.4M	Hold	3,150,808	–	–	0.19%	29
2017 Q1	$29.7M	Hold	3,150,808	–	–	0.24%	28
2016 Q4	$27.2M	Sell	3,150,808 -500,000	-14%	-$3.7M	0.27%	28
2016 Q3	$23.1M	Sell	3,650,808 -319,442	-8%	-$1.93M	0.21%	28
2016 Q2	$16.8M	Sell	3,970,250 -380,558	-9%	-$1.84M	0.18%	36
2016 Q1	$19M	Hold	4,350,808	–	–	0.2%	36
2015 Q4	$26.7M	Hold	4,350,808	–	–	0.22%	34
2015 Q3	$24.9M	Hold	4,350,808	–	–	0.23%	32
2015 Q2	$32.5M	Hold	4,350,808	–	–	0.28%	36
2015 Q1	$26M	Sell	4,350,808 -98,989	-2%	-$623K	0.22%	36
2014 Q4	$33.6M	Hold	4,449,797	–	–	0.34%	29
2014 Q3	$23.1M	Hold	4,449,797	–	–	0.29%	33
2014 Q2	$19.2M	Hold	4,449,797	–	–	0.23%	39
2014 Q1	$18.2M	Buy	4,449,797 +249,797	+6%	+$1.28M	0.23%	40
2013 Q4	$22.4M	Hold	4,200,000	–	–	0.32%	34
2013 Q3	$21.1M	Hold	4,200,000	–	–	0.3%	31
2013 Q2	$18.7M	Buy	+4,200,000	New	+$18.8M	0.37%	28

Other funds holding PGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

CTA

Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Baker Bros. Advisors's PGNX Position: Q3 2018 in Review

Baker Bros. Advisors sold out of Progenics Pharmaceuticals Inc (PGNX) in Q3 2018, closing a stake of 979,016 shares — an estimated $7.87M sold.

Baker Bros. Advisors first reported a position in PGNX in Q2 2013 and held it in 21 quarters. The position peaked at $33.6M in Q4 2014. 149 funds tracked by Wall St. Rank hold PGNX as of Q3 2018.

Baker Bros. Advisors reported no remaining Progenics Pharmaceuticals Inc position as of Q3 2018 after selling out during the quarter.
Baker Bros. Advisors sold 979,016 Progenics Pharmaceuticals Inc shares in Q3 2018, an estimated $7.87M.
Baker Bros. Advisors first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and held it in 21 quarters.
Baker Bros. Advisors's Progenics Pharmaceuticals Inc position peaked at $33.6M in Q4 2014.
149 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q3 2018.

Based on Baker Bros. Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.